NCT05401305View on ClinicalTrials.gov

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

March 30, 2020

Study Completion Date

June 17, 2020

Conditions
Haemophilus Influenzae InfectionVaccines
Interventions
BIOLOGICAL

Vaccine for the prevention of infections caused by Haemophilus influenza type b

The vaccine is administered into the region of the deltoid muscle

BIOLOGICAL

Placebo

The placebo is administered into the region of the deltoid muscle

Trial Locations (1)

Unknown

Federally Funded Healthcare Institution Primary Healthcare Unit No.163, Federal Medical-Biological Agency (FFHI PHU No.163, FMBA of Russia), Koltsovo

All Listed Sponsors
lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05401305 - Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b | Biotech Hunter | Biotech Hunter